References

Parkinson's disease

10.1016/s0140-6736(21)00218-x · 2021 · External reference

Underlying mechanisms of GBA1 in parkinson's disease and dementia with lewy bodies: narrative review

10.3390/genes16121496 · 2025 · External reference

The risk of parkinson's disease in type 1 Gaucher disease

10.1007/s10545-010-9055-0 · 2010 · External reference

10.3760/cma.j.cn113694-20200331-00233

10.3760/cma.j.cn113694-20200331-00233 · 2020 · External reference

The motor and cognitive features of parkinson's disease in patients with concurrent Gaucher disease over 2 years: a case series

10.1007/s00415-018-8908-6 · 2018 · External reference

Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher registry

10.1002/ajh.24063 · 2015 · External reference

LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the Glucocerebrosidase Gene (GBA)

10.1002/humu.20676 · 2008 · External reference

Parkinson's disease: clinical features and diagnosis

10.1136/jnnp.2007.131045 · 2008 · External reference

Classification of GBA1 variants and their impact on parkinson's disease: an in silico score analysis

10.1038/s41531-025-01060-6 · 2025 · External reference

Type I Gaucher disease with bullous pemphigoid and Parkinson disease: a case report

10.1097/md.0000000000010188 · 2018 · External reference

Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns

10.1016/j.kint.10 · 2023 · External reference

Gaucher-associated parkinsonism

10.1007/s10571-015-0176-8 · 2015 · External reference

Gaucher disease in a patient with membranoproliferative glomerulonephritis: case report

10.1186/s12882-023-03163-9 · 2023 · External reference

A 12-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease

10.1007/8904_2011_48 · 2012 · External reference

Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology

10.1038/s41531-022-00397-6 · 2022 · External reference

LaMarca ME, Stubblefield BK, et al. Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup

10.1203/01.pdr.0000049515.79882.94 · 2003 · External reference

The glucocerebrosidase D409H mutation in Gaucher disease

10.1006/bmme.1996.0077 · 1996 · External reference

Expert consensus on diagnosis and treatment of adult Gaucher disease in China

10.3760/cma.j.cn112137-20200222-00405 · 2020 · External reference

Prevalence of autoantibodies in the course of Gaucher disease type 1: a multicenter study comparing Gaucher disease patients to healthy subjects

10.1016/j.jbspin.12 · 2016 · External reference

Old disease-New reflections: Gaucher, immunity, and inflammation

10.1111/jcmm.70087 · 2024 · External reference

A review of Gaucher disease pathophysiology, clinical presentation and treatments

10.3390/ijms18020441 · 2017 · External reference

Gaucher disease and parkinsonism: a phenotypic and genotypic characterization

10.1006/mgme.2001.3201 · 2001 · External reference

Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?

10.1016/s1096-7192(03)00071-4 · 2003 · External reference

Comprehensive short and long read sequencing analysis for the Gaucher and parkinson's disease-associated GBA gene

10.1038/s42003-022-03610-7 · 2022 · External reference

Challenges in the diagnosis of parkinson's disease

10.1016/s1474-4422(21)00030-2 · 2021 · External reference

Glucocerebrosidase mutations and parkinson disease

10.1007/s00702-022-02531-3 · 2022 · External reference

Consensus guidance for genetic counseling in GBA1 variants: a focus on parkinson's disease

10.1002/mds.30006 · 2024 · External reference